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ABSTRACT _
There is a long history to our understanding of the bio-
logical basis of lipoproteins in cardiovascular disease
and to the key epidemiological studies in this field.
Building on a wealth of laboratory evidence explaining
the role of cholesterol and lipoproteins in the patho-
genesis of atherosclerosis, epidemiological studies have
characterized associations between serum lipid abnor-
malities and the risk of myocardial infarction. While el-
evation in total cholesterol has been associated with an
increased risk of myocardial infarction, this informa-
tion alone is not sufficient. To adequately predict car-
diac risk, blood cholesterol must be further character-
The societal impact of cardiovascular disease(CVD) is one of the most significant among
medical disorders in North America today. While
mortality after a myocardial infarction (MI) has been
shown to vary between 7% and 15% [1], further ev-
idence demonstrates that over half the patients sur-
viving an infarct are left with major functional im-
pairment resulting in work disability. Only about
one third of those undergoing coronary artery revas-
cularization by angioplasty or surgery experience an
increase in left ventricular function, permitting a re-
turn to work and resumption of a normal quality of
life [11. To emphasize the importance of lipid ther-
apy in preventing CVD and its consequences, this
presentation surveys current knowledge of the bio-
logical basis of lipoproteins in CVD and highlights
key epidemiological studies in this field.
Lipoprotein Mechanisms of Atherosclerosis
Coronary atherosclerosis is the etiologic condition
largely responsible for ischemic heart disease. While
association of long-term dyslipidernias with CVD
is well established, recent evidence further suggests
that acute increases in dietary fat intake impede
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ized by the high density lipoprotein (HDL) cholesterol
present and the ratio of total cholesterol to HDL cho-
lesterol. Several other factors, including such clinical
syndromes as the "deadly quartet" of insulin resistance,
central obesity, high triglycerides, and hypertension, are
also associated with a markedly increased cardiac risk
and should be identified; these may require unique ther-
apeutic approaches. In addition to the costs of tertiary
prevention and therapy after infarct, the impact of
long-term morbidity and the economic consequences of
this disease further emphasize the importance of opti-
mizing current therapies and actual practice.
endothelial function and reduce blood flow [Z].
Elucidation of the receptor-mediated pathways for
cholesterol metabolism by Brown and Goldstein
demonstrated that certain abnormal low density
lipoprotein (LDL) receptors mediate excessive in-
corporation of cholesterol into cells-a process
thought to be important in the pathogenesis of
atherosclerosis [3]. Building upon these findings, it
was discovered that humans with abnormal vari-
ants of apoprotein E (a protein that interacts with
LDL receptors) exhibit increased LDL cholesterol
and triglyceride levels, predisposing these individu-
als to atherosclerosis and CVD [4,51. Another rec-
ognized pathophysiologic element of atherosclero-
sis is cellular-level oxidation, which may mediate
endothelial injury and accelerate the process of
atherosclerosis. This has led to studies of the bene-
ficial effects of antioxidants such as vitamin E.
Epidemiologic Data
Antioxidants
Observational data from the Harvard Nurses Study
showed that, while dietary intake of foods rich in
antioxidant compounds (e.g., broccoli, spinach, and
asparagus) had no beneficial effect, nurses who
chronically ingested vitamin E supplements had a
lower MI rate 8 years into the study [6]. More rig-
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orous data from a pro specti ve cont ro lled trial co n-
du cted in Britain sho wed that vita min E reduced
the Ml rate, although no change in mortality was
observed [7]. Anoth er antioxidant that has been
studied in prospective clinical trial s is beta-caro-
tene, a ca ro t ino id . These stu dies showed that ciga-
rette smo kers receiving beta-carotene had increased
lung ca ncer and morta lity ra tes [8]. Fu rt her data
fro m the Lipid Research Cl inic (LRC) Coronary
Primary Prevention T rial and Fo llow-up Study,
unl ike th e H arvard Nurses Study , ind ica ted that
peopl e with high levels o f natural carotinoids had
a significant ly lower ra te of Ml [9) .
Across Age and Gender
Now entering its fourth generatio n of study popu-
lation , the Framingham Heart Study first showed
that young men with eleva ted chol esterollevcls had
higher MI rate s [10] . Wi th increasing age, the corre-
lation between seru m cho lesterol and infarct ion rate
was observed to be even stronger. H owever, the im-
plications of elevated cho lesterol for men over the
age of 65 have been somewhat controversial. Fol-
lowing limited studies that seemed to minimize the
impact of elevated cholesterol in elderly men, Amer-
ican College of Physician guidelines do not recom-
mend routine mea surement of serum cholesterol for
those over the age of 65 [II]. But, a meta-an alysis
from the Na tional H ear t, Lung and Blood Institute
(NHLBI) suggested that elevated cho lesterol in men
over age 65 was more pred ictive of cardiac risk than
had been previou sly thought [12]. Given a IS-year
life expectancy for those reaching age 70 without
havin g had an Ml, an d a very high rate of postinfarct
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chronic disability, guidelines for lipid therapy above
the age of 65 need to be reconsidered.
The major distinction between men and women
regarding cardiac risk is the issue of pre- versu s
postmenopausal risk in women. While the occur-
rence of premenopausa l coronary disease in women
is qu ite ra re and usually asso ciated with familial hy-
percholesterolemia, M I rates in women generally
approach those of men within 6 to 10 years after
menopause [13]. In fact , in the United States, more
wom en tha n men die from MIs each day.
Serum Lipoprotein and Triglyceride Measurement
While ea rly studies correlating serum cholesterol
with MI focused on total choleste ro l, prediction o f
ca rd iac risk from th ese data is d ifficult to interpret
for people w ith seru m cholesterol levels between
150 and 30 0 mgldL. The relati ve r isk of MI for in-
d ividua ls with a tota l cho lesterol of 300 mg/dL is
about five- to six-fold grea ter than that of indiv id-
uals w ith a level of 150 mg/dL. Looking at abso-
lute risk (Fig. 1), = 90% of those wi th total choles-
terol over 300 mg/dL will suffer an MI. However,
only 3 % of the general population has such high
total cho lesterol levels. Although the absolute risk
of MI for those with cholesterol levels between
150 and 200 mg/dL is only a bou t 20 %, thi s is
wh ere our attent ion sho uld be focused, since 45%
of the American populati on ha ve cho lestero l levels
in th is range and 35% of heart attacks occur in these
people. T he greatest number of MIs has been re-
ported in individuals with total cholesterol levels
around 225 mg/dL. H owever, since the absolute risk
of infarction at this cho lesterol level is about 40 %,
lipid therapy for all ind ividuals at th is level would
35% of CHI:> occurs in
peop le with a total




























Figure I Coronary heart disease: relative and absolute risk. CHD, coronary heart disease.
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also trea t the 60 % who did not require th erap y.
How do we ta rge t th ose w ith th e greates t need ?
Following more detailed ana lyses of the Framing-
ham data, the National Cholestero l Education Pro -
gram (NCEP) co ncluded that meas ur ing high den-
sity lipoprotein (H OL) cho lesterol togeth er with
tot al cholestero l would inc rease predict ive va lue
and more effective ly guide decision s abo ut lipid
therapy. T his recommendation is based on the ob-
serva tio n that wi th increasing levels of to ta l cho les-
terol , relatively low levels of HOL cho lestero l are
associated with greater cardiac risk, wh ereas higher
H OL cho lestero l levels ap pea r to have a protective
effect . In light of thi s informat ion, a better ap-
proach to screening is to determine the ratio of to -
tal cho lesterol to HOL as well as tot al cholesterol.
Altho ugh several other types of lipopr oteins have
been measured and seve ra l stu d ies have ad vocated
the measurement of different ratio s such as th e
LDLIHOL rati o or the LDUtota l choles terol ra tio,
it is likely that th e most informa tive ratio in pred ict-
ing MI is the roral-cholesrerol-ro-Hl'rl. rat io. O ur
therapeutic ob jective for this ratio should be a value
less tha n four . Figure 2, tak en from Fra mingha m
data, illustrates the importance of this relationship
betwee n to tal and HOL cho lesterol. Th e Nationa l
Cholestero l Educatio n Progra m 2 (NCEP2) guide-
lines [ 14] have set three LOL values as the goal of
therapy: 160, 130, and 100 mg/dL. Yet, in the
United States, the average LDL level of those having
heart attacks is 150 mg/dL [IS], while 35% of all
attac ks occur with a to tal cho lesterol level less than
200 mg/dL (first row of f ig. 2) [16]. Through evalu-
ation of total cholesterol with respect to HOL, we
see a gradual increase in coronary heart disea se
(CHO) as total chol esterol increases, and a much
more dramatic incre ase in CHO as HOL cholesterol
decreases. Thi s occurs at all levels of cholestero l.
ln additio n, cur rent guidelines need to include
other impor ta nt risk factors such as hyperte nsion,
cigarette smo king, diab etes, ECG abnormalities, or
left ventricular hypertrophy. T he latest and best
"sco re card" can be found from Framingham [17].
Data from the framingham study sugges t th at
elevated serum tr iglycer ide levels are also assoc i-
ated with increased risk of infarction. W hi le Hull y
et al. suggested th at , a fte r adj ustment fo r HOL, an
elevated triglycer ide level wa s not an independent
risk facto r [18], dat a from Hock inson and Austin
suggest the opposite-that afte r adjus tment for
H OI., an elevated tri glyceride level w as an ind e-
penden t risk factor [19,20]. H owever, as with to-
tal cho leste ro l, the interpretat ion of triglyceride
levels requires knowledge o f HDL cholesterol to
pred ict cardiac risk.
Clinical Syndromes
In th e search to identify individua ls w ith lipid ab-
normal ities and particul arl y high ca rd iac risk, spe-
cific syndromes with characteri stic clinical co nste l-
lati on s have been ob served (Ta ble 1). On e such
condition, cha racte rized by insulin res istance, high
tri glycer ides, low HOL cholesterol, an d hyperten-
sion, has been described by Reaven as "Syndrome
X" [21]. These metab ol ic d isturbances are associ-
a ted with seve ra l lipid abnormali t ies and predis-
pose affected individua ls to atherosclerosis and
CVO. Despite co nte mporary nutritional th inking,
a high-carb oh ydrate, low-fat diet actua lly exacer-
ba tes the meta bolic abnorma lities seen wi th thi s
diso rder when the tot al calories are ignored. Ka-
plan char acterized thi s syndrome, including insu-
lin resistance, central ob esity, high triglycerides,
and hypertension, as the " dea dly qua rte t " [22].
Studies of monozygotic tw ins performed with the
Natio na l Heart, Lun g and Blood Institute showed
indivi dua ls with high tri glyceride and low HOL
pr ofiles had three tim es the risk of infarct ion th an
Figure 2 Coro nary heart disease: total
and HDL cholesterol in men and women.
aged 50-79 yea rs. CHD, co ronary heart
disease; HDL, high density lipoprotein .
(Adapted from Fram ingham Heart Study!
National Hea rt, Lung and Blood Institute
data.)
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Table I Clinical syndromes related to increased risk of
coronary heart disease*
with the assistance of BioMedCom Consultants mc.,
Montreal, Canada.
This paper is based on the presentation of William Cas-
telli at the ISPOR Lipid Conference and was prepared
*Syndrome X [21], Deadly Quartet [22], Dyslipidemic Hypertension [29],
Insulin Resistance Syndrome (IRS) [30], and Polymetabolic Syndrome [31].
HDL, high density lipoprotein; LDl, low density lipoprotein; PAl-I, plasmino-
gen activator-I; VLDL,very low density lipoprotein.
their normal twins. Hypertension was associated
with a 4-fold risk, and individuals with the full
syndrome had a la-fold risk increase [23]. Women
with the "deadly quartet" appear to be at greatest
risk with twice that of other affected subgroups.
Further investigation of the metabolic abnormali-
ties of individuals has provided us with insight
into the many molecular components involved in
the disease process: various types of very low den-
sity lipoproteins (VLDLs), seven types of LDLs,
and their dynamic relationship with HDL and
triglyceride levels [24]. It has also led to the novel
identification of mediators such as plasminogen
activator-l (PAl-l), little A protein (LP(a)), and el-
evated levels of homocysteine, all of which are im-
plicated in accelerated thrombogenesis [25].
Conclusions
Epidemiological studies have furthered our under-
standing of the role of lipid abnormalities in the
occurrence of CVD. Together with this epidemio-
logical data, therapeutic trials have demonstrated
the merits of lipid therapy in CVD prevention. Re-
cent trials such as the treatment of asymptomatic
men in Scotland [26] and asymptomatic men and
women in Texas [27] have shown dramatic reduc-
tion in coronary heart disease, surgical procedures,
and stroke, as have similar studies in secondary
prevention [28]. Considering the costs of preven-
tion and post-Ml therapy, as well as the long-term
morbidity and economic impact of this disease, the
importance of providing and improving current
lipid therapy cannot be too strongly emphasized.
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